Adalimumab biosimilar (Trpharm)

阿达木单抗生物类似药 (Trpharm)

Report date: 2024/06/07 17:16:08

Base Information

Drug NameAdalimumab biosimilar (Trpharm)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar

Mechanisms of ActionTumor necrosis factor α inhibitors

TargetsTumor necrosis factor α

Therapy Area/IndicationsArthritis, Rheumatoid

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesTrpharm

China Registration ClassN/A

Active CompaniesTrpharm

Inactive CompaniesN/A

Active IndicationsArthritis, Rheumatoid

Inactive IndicationsN/A

ATC CodeN/A